Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. - Wikidata - awgldk - TriplyDB

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

http://www.wikidata.org/entity/Q34448251

about

Critical Questions about PARADIGM-HF and the Future Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan Pharmacological Therapy in the Heart as an Alternative to Cellular Therapy: A Place for the Brain Natriuretic Peptide?Recent advances in treatment of heart failure A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date Sacubitril/valsartan in heart failure: latest evidence and place in therapy From ARB to ARNI in Cardiovascular Control Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm Silent disease progression in clinically stable heart failure.Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study.Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging.Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis.Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.New medications for heart failure.The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.The Three-Decade Long Journey in Heart Failure Drug Development.LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.The Current and Potential Clinical Relevance of Heart Failure Biomarkers.New medical therapies for heart failure.Using biomarkers to guide heart failure management.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Sacubitril/valsartan (LCZ696) for the treatment of heart failure.Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies.Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach.

P2860

Q26741029-9005FFC9-3D25-4526-B21B-E353089C80E0 Q26746907-8F4F4193-A829-4F77-B754-EA0640E7AB4C Q26747165-C7A2E191-3E7B-442C-9B55-B137A1ED8891 Q26765883-A4A21049-88B1-4CC6-94A5-12108EA1A9BE Q26766223-193BC499-D14A-4B3D-9083-1D005206A19D Q26770151-77BC13E7-DD50-4D83-B9EB-F23AC3731B1F Q27027707-7633109C-839F-41A0-8698-9970DE4D2AE8 Q28070064-3B1AC7E0-8696-4092-9EC5-682F2371DF2C Q28070191-85C14CCA-353C-48F5-8BE6-F0A38282FE35 Q28073372-BEBDAE74-186F-4B04-96C4-E513FCEB2D90 Q28077186-1F2217D9-EE91-405A-9E6D-A8DEFAF8CD86 Q33578212-58A4DC6B-FB35-4C4A-A575-DBA6AB90809D Q33751504-4BBB95AB-14AC-4B58-A316-848AC39382B6 Q33862358-E3C88D93-E8A8-48FF-924C-F82FAB862167 Q34485114-C689B729-3809-477C-8CAF-F487B087D90F Q34495751-459C9632-FF16-44D2-81A9-48B56A85E5AB Q35101841-1E1E2504-4229-464D-8685-CE037643C3ED Q35842030-924824FB-0052-4635-88E3-6D46787937C4 Q36003962-5E5AB2EE-545A-449B-9264-CDFF0E10A119 Q36054705-20A0FA5D-F95A-4B0E-82C0-19AA8E1142AE Q36069585-CF2BFF6B-A712-411D-AC30-4CBD3A31BD68 Q36128797-B62DEB21-2017-4BBC-96AE-E68E7DC4A36C Q36736998-9C9A84DF-9416-422B-9794-94652B4E1227 Q36860608-50420BD1-57DE-4E91-83F4-CC3CF95F10E8 Q37583865-22094E71-1F00-4187-B20E-226CDF135889 Q37595978-8089BA4A-08E5-4E3C-8A06-F0FDA95BB815 Q37597972-FC113860-CE7C-4935-A58D-D77CAA364A86 Q38429870-F77AD0D9-EBF3-407C-A765-B21F2A6A062D Q38534772-94076B32-90D2-4D0D-B0D5-559350D28C4E Q38546656-8B3B98AD-5937-4554-A853-30CE86DBB247 Q38551693-4C614D20-94AE-4843-B2A5-A16597BF58AA Q38558614-06A382E8-FDA1-47B5-AA67-0466D7218EC2 Q38568202-D37AAC85-621B-43D6-B305-C451A3EC3ECF Q38568205-75D62CA2-80FD-4132-8A8A-0D816AC07829 Q38594785-0A518B77-2276-4ECB-990C-47F0955A1602 Q38613842-36B44D01-2770-4D9B-A45F-E4064144E982 Q38614176-01BE7477-91EC-4355-BCF9-6A6885C7F6D8 Q38661061-547C0384-22E2-431F-A0B0-A4474C4CF3C8 Q38709338-CFCBE11D-18C2-4D9E-8379-96A1AC05FF86 Q38709514-D6FD34D1-DE87-4ABC-A101-A2CFB7ACCC9D

P2860

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

http://www.wikidata.org/entity/Q34448251

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Angiotensin receptor neprilysi ...... g patients with heart failure.

@ast

Angiotensin receptor neprilysi ...... g patients with heart failure.

@en

Angiotensin receptor neprilysi ...... g patients with heart failure.

@nl

type

label

Angiotensin receptor neprilysi ...... g patients with heart failure.

@ast

Angiotensin receptor neprilysi ...... g patients with heart failure.

@en

Angiotensin receptor neprilysi ...... g patients with heart failure.

@nl

prefLabel

Angiotensin receptor neprilysi ...... g patients with heart failure.

@ast

Angiotensin receptor neprilysi ...... g patients with heart failure.

@en

Angiotensin receptor neprilysi ...... g patients with heart failure.

@nl

P1433

Q34448251-85D251D5-0B25-422E-BC5C-4B1D50D03879

P1476

Q34448251-2218A6C1-B6F3-4798-B9CC-3678F2BE39B6

P2093

Q34448251-04AB7273-802C-4593-9D82-E56050A3922D

Q34448251-0CF4F653-C3C0-4484-BB30-F90655BA833C

Q34448251-0DE891FF-09D5-47D4-B483-ADE3FB8EB4A3

Q34448251-1AB3246A-86F3-4293-BAAE-FC713ACDC16D

Q34448251-1EAD4210-BB48-49E9-B35F-7E281F51068E

Q34448251-1EF86FE9-BF4E-4E66-AB0B-0022A4B020DC

Q34448251-209A30D8-8DB7-44D7-A9BB-E8C1DBAE0356

Q34448251-21EEED93-4070-4374-A21A-298CDA126322

Q34448251-2201518A-8C6D-4F06-98A6-30E3397D2E8D

Q34448251-2CE84028-DB5A-4C36-B601-CD950577D420

P304

Q34448251-4186E704-DC57-4B6C-B5F2-BB891A609DFE

P31

Q34448251-96B62A73-03A8-4C32-ADC0-F45E1B65FD37

P356

Q34448251-4468822D-68FD-4300-A378-4F0799FD84E5

P407

Q34448251-6BEA1685-B28C-42D4-B4DC-BBC412E56BFB

P433

Q34448251-568F7C60-E4F5-4899-9AF1-D1D1834534EF

P478

Q34448251-CCECEF6B-F982-4E2F-8437-DDA76C287B0A

P50

Q34448251-4AA1D172-338F-42BB-98BA-7AE1A5131BCC

Q34448251-76B55DD1-B9D0-4B2E-AB11-DB0B6BE382CD

Q34448251-7E9E31A9-FFA0-4C27-89F0-AB42C7411A5A

Q34448251-F180FB75-BB13-4878-9B4E-5BC2F495A444

P577

Q34448251-FD81AD9F-EDE6-41A6-AA4B-6046ADF0B658

P698

Q34448251-594CA6E5-1014-455E-BD7F-4446945733F4

P921

Q34448251-CDD2F109-C689-4F76-8211-004DB6FAA454

Q34448251-F50F0A92-ACB6-4B7E-A916-AE96578A946D

P356

CIRCULATIONAHA.114.013748

P1433

P1476

Angiotensin receptor neprilysi ...... g patients with heart failure.

@en

P2093

Adel R Rizkala

http://www.w3.org/2001/XMLSchema#string

Akshay S Desai

http://www.w3.org/2001/XMLSchema#string

Albert A Hagège

http://www.w3.org/2001/XMLSchema#string

Andrej Dukat

http://www.w3.org/2001/XMLSchema#string

Andrejs Erglis

http://www.w3.org/2001/XMLSchema#string

Angel Gonzàlez-Medina

http://www.w3.org/2001/XMLSchema#string

Antonio S Sibulo

http://www.w3.org/2001/XMLSchema#string

Arend Mosterd

http://www.w3.org/2001/XMLSchema#string

Arvo Rosenthal

http://www.w3.org/2001/XMLSchema#string

Bela Merkely

http://www.w3.org/2001/XMLSchema#string

P304

54-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.114.013748

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Randall C Starling

P577

2014-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25403646

http://www.w3.org/2001/XMLSchema#string

P921